Morphic Holding Inc

Morphic — Investor Presentation (March 2024)

38 slides from Morphic's investor presentation, Mar 12, 2024

  1. Slide 1: Delivering A New Generation Of Integrin Medicines

    Delivering A New Generation Of Integrin Medicines March 2024

  2. Slide 2: Forward-Looking Statements

    This presentation contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the timing and success of Morphic’s ongoing clinical trials and related data, updates

  3. Slide 3: Unique Receptors: Unique Therapeutic Potential

    Unique Receptors: Unique Therapeutic Potential 3 What are integrins? • Only receptor to signal bidirectionally, giving them central biologic roles in complex diseases: autoimmune, fibrotic, cardio-metabolic and oncologic • Expensive, complex biologics have shown clinically meaningful efficacy by tar

  4. Slide 4: MInT Platform: Morphic's Solution to the Oral Integrin Challenge

    MInT Platform: Morphic’s Solution to the Oral Integrin Challenge 4 Structural Knowledge Privileged Scaffolds Focused Chemical Libraries Assays Against Tractable Targets Synthetically Tractable “Hits” Computational Chemistry w/ Schrödinger High Quality Probes Pharmacologic Validation of Related Targe

  5. Slide 5: Proprietary Pipeline

    Proprietary Pipeline 5 Candidate Target (Program) Indication Discovery IND-enabling Phase 1 Phase 2 Phase 3 MORF-057 α4β7 Ulcerative Colitis Crohn's disease1 Next- generation α4β7 GI Disorders MORF SMI2 IL23, TL1A, etc Immune and Inflammatory Diseases MORF SMI α5β1 Pulmonary Hypertensive Diseases MO

  6. Slide 6: MORF-057 Small molecule inhibitor of α4β7

    MORF-057 Small molecule inhibitor of α4β7: a well-validated mechanism to treat IBD EMERALD-2 Phase 2b study ongoing

  7. Slide 7: IBD: Ideal Future Treatment Paradigm

    IBD: Ideal Future Treatment Paradigm 7 COMBINABLE ORAL WELL TOLERATED EFFICACIOUS

  8. Slide 8: First-In-Class Oral Integrin Drug for IBD

    Indications First-In-Class Oral Integrin Drug for IBD 8 Highly selective orally available small molecule inhibitor of α4β7, well validated mechanism for the treatment of IBD through approved monoclonal antibody vedolizumab MORF-057 Occluding α4β7 blocks intestinal homing of lymphocytes, which in tur

  9. Slide 9: α4β7 Inhibition is a Proven Mechanism to Treat IBD

    α4β7 Inhibition is a Proven Mechanism to Treat IBD • Approved antibody Entyvio® (vedolizumab) • Vedolizumab, an anti-α4β7 antibody, inhibits T-cell trafficking via well validated mechanism to treat UC and Crohn’s disease • Since approval, over 265,000 patients have received vedolizumab1 • Vedolizuma

  10. Slide 10: MORF-057 has Consistently Delivered on Expectations for an Oral α4β7 Inhibitor in IBD

    MORF-057 has Consistently Delivered on Expectations for an Oral α4β7 Inhibitor in IBD 10 MORF-057 PRECLINICAL PHASE 1 PHASE 2a Oral Route of Administration Favorable Tolerability Profile α4β7 Saturation (serum) 30-50% ↑ in Key Lymphocytes Meaningful Clinical Effects All scientific posters and presen

  11. Slide 11: EMERALD-1 Phase 2a Study of MORF-057

    EMERALD-1 Phase 2a Study of MORF-057

  12. Slide 12: MORF-057 Phase 2a: EMERALD-1 Study in Moderate to Severe UC

    MORF-057 Phase 2a: EMERALD-1Study in Moderate to Severe UC 12 Study Visits W0 D1 W2 D15 W6 D43 W12 D85 W20 D141 W28 D197 W36 D253 W44 D309 W52/EOT D365 W82/SFU D575 W56/SFU D393 W65 D456 W78/EOT D547 W - 6 to -1 D - 42 to -1 Phase 2a open-label single-arm study of MORF-057 (100mg BID) in patients wi

  13. Slide 13: Baseline Patient Demographics

    Category Patients, N=35 Age, mean ± SD Years 39.2 ± 14.1 Sex, n (%) Female 16 (45.7) Geography, n (%) Poland United States 28 (80.0) 7 (20.0) Duration of disease, mean ± SD Years 7.5 ± 8.0 Extent of disease, n (%) Proctosigmoiditis L-sided colitis Pancolitis 12 (34.3) 10 (28.6) 10 (28.6) RHI Score,

  14. Slide 14: EMERALD-1 12-week Induction Phase

    EMERALD-1 12-week Induction Phase Data as of 4/25/23

  15. Slide 15: Generally Well-Tolerated in EMERALD-1

    Generally Well-Tolerated in EMERALD-1 No Safety Signal Observed 15 Adverse Event (AE) profile consistent with underlying disease state Patients with at least one AE 12 (34.3%) Patients with any serious AE 0 Patients with AE leading to death 0 Patients with any grade 3 AE 2 (5.7%)1 Patients with trea

  16. Slide 16: Patient α4β7 Receptor Occupancy Consistent with Healthy Volunteer RO

    Patient a4β7 Receptor Occupancy (RO) Consistent with Healthy Volunteer RO 16 a4β7 selectivity over a4β1 consistent with Phase 1 results RO at 12 weeks a4β7 a4β1 Mean >98% BLQ Median >99% BLQ • a4β7 RO achieved early and sustained saturating levels • a4β1 RO remained at low levels • No lymphocytosis

  17. Slide 17: Fecal Calprotectin Decreases Correlated with Disease Improvement

    17 Fecal Calprotectin Decreases Correlated with Disease Improvement 19% 54% 75% Overall (n=29): 35% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Non- Responder (n=16) Clinical Response (n=13) Clinical Remission (n=8) -11% -86% -89% Overall (n=27): -56% -100% -90% -80% -70% -60% -50% -40% -30% -20% -1

  18. Slide 18: Substantial Lymphocyte Subset Changes Observed

    18 Substantial Lymphocyte Subset Changes Observed, Consistent With Engagement Of α4β7 0 25 50 75 100 125 150 Weeks N o rm a li z e d % 0 2 6 12 0 25 50 75 100 125 150 200 300 400 Weeks N o rm a li z e d % P = 0.0039 ** 0 2 6 12 P = 0.0298 * 0 25 50 75 100 125 150 200 300 400 Weeks N o rm a li z e d

  19. Slide 19: EMERALD-1 Induction Phase Clinical Efficacy Results

    EMERALD-1 Induction Phase Clinical Efficacy Results

  20. Slide 20: Primary Endpoint Met with Statistical Significance

    20 Endpoint @ Week 12 Overall (N=35) Change in RHI, Mean (SD) -6.4 (11.18) p=0.0019 RHI remission, n (%) 8 (22.9%) Clinical response (mMCS)1, n (%) 16 (45.7%) Clinical remission (mMCS)2, n (%) 9 (25.7%) Endoscopic Response/Improvement3, n (%) 9 (25.7%) Change from baseline to Week 12 in the Modified

  21. Slide 21: EMERALD-1 Efficacy Results by AT Status and MES

    21 EMERALD-1 Efficacy Results by AT Status and MES Endpoint @ Week 12 Overall N=35 AT-naïve n=21 AT- experienced n=14 MES =2 n=18 MES =3 n= 17 Change in RHI, mean ± SD -6.4 ± 11.2 -7.4 ± 11.9 -4.8 ± 10.3 -6.9 ± 12.1 -5.8 ± 10.4 RHI change ≥ 7 points, n (%) 17 (48.6) 12 (57.1) 5 (35.7) 10 (55.6) 7 (4

  22. Slide 22: Consistent Across-the-Board Efficacy Signals Observed

    22 Consistent “Across-the-Board” Efficacy Signals Observed Subgroup AT-Experienced Yes (n=14) No (n=21) Corticosteroid Use at Baseline Yes (n=9) No (n=26) Baseline MES 3 (n=17) 2 (n=18) Mean Change (95% CI) -4.8 (-10.7, 1.1) -7.4 (-12.8, -2.0) -5.2 (-11.1, 0.7) -6.8 (-11.7, -1.8) -5.8 (-11.1, -0.4)

  23. Slide 23: Clinical Improvement in >75% of All Patients

    23 Clinical Improvement in >75% of All Patients, Regardless of Prior Therapy and Baseline MES 77% 46% 26% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% Improvement in mMCS Clinical Response Clinical Remission Overall Clinical Improvement AT-Naïve: n=21; AT-Experienced: n=14 76% 52% 43% 79% 36% 0% 0% 10% 20

  24. Slide 24: Change in Central mMCS By Patient from Baseline

    24 Change in Central mMCS By Patient from Baseline at Week 12 -7 -6 -5 -4 -3 -2 -1 0 1 2 C h an ge in m M C S fr o m B as el in e at W ee k 1 2

  25. Slide 25: EMERALD-1 Data Beyond Weeks

    EMERALD-1 Data Beyond 12 Weeks

  26. Slide 26: Symptomatic Remission By AT-Status

    26 Symptomatic Remission By AT-Status: Week 44 Intent to Treat (ITT): Denominator includes all enrolled patients (N=35) As observed: Denominator includes only patients who completed the visit 14.3 7.1 11.4 42.9 7.1 28.6 47.6 7.1 31.4 42.9 21.4 34.3 47.6 28.6 40 42.9 28.6 37.1 42.9 21.4 34.3 3/21 9/2

  27. Slide 27: MORF-057 Phase 2b: EMERALD-2 Study in Moderate to Severe UC

    MORF-057 Phase 2b: EMERALD-2 Study in Moderate to Severe UC 27 Induction Period (12 weeks) Maintenance Period (40 weeks) Primary Endpoint: proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS) W0 D1 W2 D15 W6 D43 W12 D85 W18 D127 W24 D1

  28. Slide 28: GARNET Phase 2 Study in Moderate to Severe Crohn's Disease

    GARNET Phase 2 Study of MORF-057 in Moderate to Severe Crohn’s Disease 28 Induction Period (14 weeks) Maintenance Period (38 weeks) Primary Endpoint: proportion of patients with endoscopic response (>=50% reduction) at week 14 as determined using SES-CD Open-label Extension Safety Follow-Up Period S

  29. Slide 29: Emerging Pipeline

    EMERGING PIPELINE Creating the next generation of proprietary integrin inhibitor candidates

  30. Slide 30: α5β1: Small Molecule Integrin Inhibitor for Pulmonary Hypertensive Diseases

    a5β1: Small Molecule Integrin Inhibitor for Pulmonary Hypertensive Diseases 30 Small molecule inhibitors of fibronectin integrins in preclinical development Program Fibronectin integrin inhibition suppresses pulmonary arterial smooth muscle cell proliferation Indications Multiple pulmonary hypertens

  31. Slide 31: α5β1 Integrin Inhibition for Pulmonary Hypertensive Diseases

    Vasoconstriction Arterial remodeling & inflammation Pulmonary Hypertensive Diseases a5β1 Integrin Inhibition for Pulmonary Hypertensive Diseases • Potential applications in severely underserved pulmonary hypertensive diseases • In preclinical studies, Α5β1 inhibition may drive multiple independent p

  32. Slide 32: α5β1 Inhibition Improves Pulmonary Artery Remodeling and Cardiac Function

    32 a5b1 Inhibition Improves Pulmonary Artery Remodeling and Cardiac Function Data generated by Sebastien Bonnet, Laval University Mean ± SEM. *p<0.05; **p<0.01; ***p<0.001 One-way ANOVA followed by Dunnett’s test vs. Vehicle MT-200 = a5β1/av small molecule inhibitor; (100 mg/kg, PO BID). SOC = Macit

  33. Slide 33: α5β1 Inhibition Blocks Smooth Muscle Cell Proliferation in Human PAH Lung Slices

    Study assessed the use of precision cut lung slices (PCLS) from human PAH patients to assess vascular remodeling ex vivo Impressive inhibition of pulmonary artery remodeling achieved in this human system 33 a5β1 Inhibition Blocks Pulmonary Artery Smooth Muscle Cell Proliferation in Human PAH Lung Sl

  34. Slide 34: αvβ8 Small Molecule Integrin Inhibitor Program

    avβ8 Small Molecule Integrin Inhibitor Program for Myelofibrosis and Immuno-oncology 34 Small molecule inhibitors of the αvβ8 integrin in preclinical development avβ8 Program αvβ8 inhibition suppresses activation of TGFβ isoforms 1 and 3 Indications Myelofibrosis; Combination therapy for solid tumor

  35. Slide 35: MORF-088: αvβ8 Inhibitor for Myelofibrosis

    MORF-088: αvβ8 Inhibitor for Myelofibrosis (MF) • MF: multi-mechanistic etiology including TGF-B • Blockbuster rare disease indication – Jakafi $1 billion MF sales alone • No disease modifying Tx except allogeneic hematopoietic stem cell transplant • Current SoC has multiple deficiencies • Toxicity:

  36. Slide 36: αvβ8 Inhibition: Central Role in TGF-β Modulation

    36 avβ8 Inhibition: Central Role in TGF-b Modulation HD MF HEL 0.000 0.001 0.002 0.003 0.004 0.005 ITGB8 G e n e E x p . re la ti v e t o G A P D H 0.0402 HD MF JVM-2 0.000 0.001 0.002 0.003 0.004 0.005 ITGB6 G e n e E x p . re la ti v e t o G A P D H 0.5566 Healthy donor (HD) and myelofibrosis (MF)

  37. Slide 37: Deep Specialist Expertise Across Management and Board of Directors

    Deep Specialist Expertise Across Management, and Board of Directors Gustav Christensen, MBA Chairman Morphic Board, former CEO, Dyax Timothy Springer, PhD Founder, Morphic Therapeutic, Member of Morphic Scientific Advisory Board; Latham Family Professor, Professor of Biological Chemistry and Molecul

  38. Slide 38: Thank You

    THANK YOU

Morphic Holding — Investor Presentation (March 2024) on 6ix